Respiratory News and Research

RSS

Gadavist approved by FDA for use in central nervous system MRI scans

The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

16 Mar 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

SOM Biotech closes first financing round and files patent application

SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.

14 Mar 2011

EMP levels may help clinicians diagnose early emphysema

Monitoring blood for tiny particles released by cells lining the lungs may help clinicians diagnose emphysema in its earliest stages, according to researchers from Weill Cornell Medical College. The particles, called endothelial microparticles, are shed during the disease process as tiny blood vessels in the lungs, called pulmonary capillaries, are injured and die.

14 Mar 2011

Novel biomarkers may aid in diagnosis and management of asthma, COPD

Four novel biomarkers have been identified which may aid in the diagnosis and management of asthma and chronic obstructive pulmonary disease, according to a study conducted by researchers in Australia, who determined the biomarkers may be used in different combinations to successfully identify patients with either of the airway diseases.

14 Mar 2011

Test that measures destruction of lung air sacs, could help prevent progression of emphysema

During a regular annual physical exam, blood is usually drawn to check the health of a person's heart, kidneys and liver. Now, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center say a blood test that detects the early development of emphysema -- well before symptoms occur -- may someday also be offered.

12 Mar 2011

Researchers uncover new disease mechanism in patients with CGD

Infection researchers at Umeå University have uncovered a new disease mechanism in patients with Chronic Granulomatous Disease in an international clinical collaboration with the Children's Hospital in Zurich.

11 Mar 2011

Infant formulas with fluoridated water increase risk of discolored teeth: HHS

All infant formulas, either concentrated or ready-to-feed, already contain some fluoride and, when routinely mixed with fluoridated water, increase the risk of dental fluorosis, according to Dr. Howard Koh, Assistant Secretary for Health, U.S. Department of Health and Human Services in a video commentary published on Medscape.com, March 8, 2011.

11 Mar 2011

Iron deficiency during pregnancy may directly impact infant breathing health

Need a reason to take your iron supplements? Iron deficiency during pregnancy may directly impact infant and childhood breathing health according to a study recently published in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Swine flu virus may evolve into a deadlier form

In the fall of 1917, a new strain of influenza swirled around the globe. At first, it resembled a typical flu epidemic: Most deaths occurred among the elderly, while younger people recovered quickly. However, in the summer of 1918, a deadlier version of the same virus began spreading, with disastrous consequence. In total, the pandemic killed at least 50 million people - about 3 percent of the world's population at the time.

10 Mar 2011

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations.

10 Mar 2011

Tiniest pollution particles can contribute to cardiovascular disease in diabetic people

Scientists are untangling how the tiniest pollution particles - which we take in with every breath we breathe - affect our health, making people more vulnerable to cardiovascular and respiratory problems.

10 Mar 2011

MHQP reports significant differences in quality of care delivered by Massachusetts medical groups

Massachusetts Health Quality Partners announced today that despite improvement, there are significant differences in the quality of care delivered by medical groups in Massachusetts, according to its annual Quality Insights: Clinical Quality in Primary Care report.

9 Mar 2011

Three new research initiatives to study how design of neighbourhoods impact obesity

The Honourable Leona Aglukkaq, Minister of Health, today announced three new research initiatives studying how the design of neighbourhoods impact obesity. The studies were funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada.

9 Mar 2011

ImpactRx adds pulmonologists to physician specialty panels network

ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior announced today that it is expanding its nationwide network of longitudinal panels of iPhone-connected physicians with the addition of the pulmonologist specialty.

9 Mar 2011

Pulse Health's Revelar device helps minimize free radical damage

Pulse Health announces Revelar the first non-invasive device to help healthcare professionals and their patients measure aldehydes and help minimize free radical damage. Revelar is breakthrough breath technology that accurately detects and measures the presence of aldehydes, which are indicators of free radical damage in the body.

9 Mar 2011

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

In a move to improve efficiency by reducing paper in their respective operations, Forest Laboratories and the Allergy Asthma Research Institute have joined SAFE-BioPharma Association. They now have access to the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

9 Mar 2011